Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform

References

• Teneriello MG, Park RC. Early detection of ovarian cancer. CA Cancer J Clin 1995;45:71–87.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer facts & figures 2010. Atlanta: American Cancer Society; 2010.
   Google Scholar
• Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004;3:355–66.
   PubMed Web of Science ®Google Scholar
• Williams TI, Toups KL, Saggese DA, Kalli KR, Cliby WA, Muddiman DC. Epithelial ovarian cancer: Disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers. J Proteome Res 2007;6:2936–62.
   PubMedGoogle Scholar
• Li M, Wang B, Zhang M, Rantalainen M, Wang S, Zhou H, . Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci USA 2008;105:2117–22.
   PubMed Web of Science ®Google Scholar
• Cao H, Huang H, Xu W, Chen D, Yu J, Li J, . Fecal metabolome profiling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography-mass spectrometry. Anal Chim Acta 2011;691:68–75.
   PubMedGoogle Scholar
• Gold J. Metabolic profiles in human solid tumors. I. A new technic for the utilization of human solid tumors in cancer research and its application to the anerobic glycolysis of isologous benign and malignant colon tissues. Cancer Res 1966;26:695–705.
   PubMedGoogle Scholar
• Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat Rev Cancer 2004;4:551–61.
   PubMed Web of Science ®Google Scholar
• Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, . Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009;457:910–4.
   PubMed Web of Science ®Google Scholar
• Gowda GA, Zhang S, Gu H, Asiago V, Shanaiah N, Raftery D. Metabolomics-based methods for early disease diagnostics. Expert Rev Mol Diagn 2008;8:617–33.
   PubMed Web of Science ®Google Scholar
• Bartella L, Thakur SB, Morris EA, Dershaw DD, Huang W, Chough E, . Enhancing nonmass lesions in the breast: Evaluation with proton (1H) MR spectroscopy. Radiology 2007;245:80–7.
   PubMed Web of Science ®Google Scholar
• Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: A review. Clin Cancer Res 2009;15:431–40.
   PubMed Web of Science ®Google Scholar
• Odunsi K, Wollman RM, Ambrosone CB, Hutson A, McCann SE, Tammela J, . Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int J Cancer 2005; 113:782–8.
   PubMed Web of Science ®Google Scholar
• Garcia E, Andrews C, Hua J, Kim HL, Sukumaran DK, Szyperski T, . Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe. J Proteome Res 2011;10:1765–71.
   PubMedGoogle Scholar
• Chen J, Zhang X, Cao R, Lu X, Zhao S, Fekete A, . Serum 27-nor-5beta-cholestane-3,7,12,24,25 pentol glucuronide discovered by metabolomics as potential diagnostic biomarker for epithelium ovarian cancer. J Proteome Res 2011;10:2625–32.
   PubMed Web of Science ®Google Scholar
• Breiman L. Random forests. Machine Learning 2001;45:5–32.
   Web of Science ®Google Scholar
• Diaz-Uriarte R, de Andres SA. Gene selection and classification of microarray data using random forest. BMC Bioinformatics 2006;7:3.
   PubMed Web of Science ®Google Scholar
• Tcherkassova J, Abramovich C, Moro R, Chen C, Schmit R, Gerber A, . Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer. Tumour Biol 2011;32:831–8.
   PubMedGoogle Scholar
• Hannun YA, Luberto C, Argraves KM. Enzymes of sphingolipid metabolism: From modular to integrative signaling. Biochemistry 2001;40:4893–903.
   PubMed Web of Science ®Google Scholar
• Saad AF, Meacham WD, Bai A, Anelli V, Elojeimy S, Mahdy AE, . The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther 2007;6:1455–60.
   PubMed Web of Science ®Google Scholar
• Dziecedil GP, Owczarek T, Plazuk E, Gomulkiewicz A, Majchrzak M, Podhorska-Okolow M, . Ceramide galactosyltransferase (UGT8) is a molecular marker of breast cancer malignancy and lung metastases. Br J Cancer 2010;103:524–31.
   PubMedGoogle Scholar
• Sutphen R, Xu Y, Wilbanks GD, Fiorica J, Grendys EC Jr, LaPolla JP, . Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1185–91.
   PubMed Web of Science ®Google Scholar
• Monet M, Gkika D, Lehen'kyi V, Pourtier A, Vanden Abeele F, Bidaux G, . Lysophospholipids stimulate prostate cancer cell migration via TRPV2 channel activation. Biochim Biophys Acta 2009;1793:528–39.
   PubMed Web of Science ®Google Scholar
• Sengupta S, Kim KS, Berk MP, Oates R, Escobar P, Belinson J, . Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion. Oncogene 2007;26:2894–901.
   PubMed Web of Science ®Google Scholar
• Springett GM, Bonham L, Hummer A, Linkov I, Misra D, Ma C, . Lysophosphatidic acid acyltransferase-beta is a prognostic marker and therapeutic target in gynecologic malignancies. Cancer Res 2005;65:9415–25.
   PubMedGoogle Scholar
• Mocchetti I. Exogenous gangliosides, neuronal plasticity and repair, and the neurotrophins. Cell Mol Life Sci 2005;62: 2283–94.
   PubMed Web of Science ®Google Scholar
• Birkle S, Zeng G, Gao L, Yu RK, Aubry J. Role of tumor-associated gangliosides in cancer progression. Biochimie 2003;85:455–63.
   PubMed Web of Science ®Google Scholar